Updated:
Brokerage calls drove sharp moves in several stocks during the week ended October 2, 2026, as analysts reassessed credit risk, clinical prospects and valuations. Foghorn Therapeutics fell about 18% after reporting that it would not advance a partnered cancer-drug program into the next trial phase, while Swiss composites maker Gurit dropped 11.5% after UBS cut its rating despite raising its price target.
The weekly roundup published by Investing.com on October 4 selected one upgrade or downgrade for each trading day, favoring calls with reported share-price reactions and excluding rating holds and price-target-only changes. The moves it cited were mostly intraday snapshots, not closing prices, and should not be read as a comprehensive record of every analyst action that week.
Credit concerns weigh on FS KKR Capital
On Monday, September 28, Wells Fargo lowered its rating on FS KKR Capital, a business development company, to Underweight from Equal Weight and set a $10 price target. Investing.com reported the shares were trading at $11.16 when the note appeared, but did not provide a quantified percentage move linked to the downgrade.
The bank’s stated concern was the company’s troubled-loan exposure. According to the report, Wells Fargo cited $897 million of non-accrual investments at cost and argued that new problem loans were emerging more frequently than at peers. It also judged the company’s reported 15.77% dividend yield insufficient compensation for the credit risk.
Funding conditions were another concern in the discussion: Fitch had cut FS KKR Capital’s long-term issuer and senior unsecured debt ratings to BB+ from BBB- in April, retaining a negative outlook. That rating action provides context for the analyst’s focus on credit quality and financing, but it does not itself establish that the downgrade caused Monday’s share-price performance.
STAAR Surgical wins an upgrade; Commerzbank loses one
On Tuesday, September 29, Stifel raised STAAR Surgical to Buy from Hold and increased its price target to $31 from $28. The company makes implantable lenses used in vision correction. Contemporaneous reports said its shares rose about 6.4% to 7% in early trading after the change.
Stifel’s case, as summarized in the reports, centered on anticipated demand for higher-priced EVO+ lenses in China and easier comparisons in other markets. The brokerage projected an 11% compound annual revenue growth rate through 2028, compared with a consensus estimate near 8%. Those figures describe the analyst’s outlook, not company guidance or realized growth.
A day later, Deutsche Bank moved in the opposite direction on Commerzbank, cutting the German lender to Hold from Buy while keeping its target at €42. The shares had closed at €42.38 before the call, and Investing.com reported a fall of more than 2% after the downgrade.
Analyst Benjamin Goy’s concerns included whether the share price already reflected the benefits of higher net interest income and buybacks. Uncertainty about UniCredit’s possible move involving the lender was also described as a constraint on further valuation gains. The rating change was an analyst judgment, not an announcement of a completed transaction or a change in Commerzbank’s own plans.
Foghorn’s drug-program decision triggers the week’s steepest move
On Thursday, October 1, Foghorn Therapeutics announced that it and Eli Lilly would not move FHD-909 into the expansion stage of its clinical development after reviewing Phase 1 dose-escalation data. Foghorn’s filing said the partners had observed clinical results that led them not to advance the program; the company described the drug as selectively targeting SMARCA2 and said it had a favorable safety profile at exposures above preclinical targets.
Citizens cut its rating to Market Perform from Market Outperform, and Investing.com reported Foghorn shares fell from a prior close of $3.52 to $2.88, a decline of about 18.2%. A separate report on the same day cited an 18.21% fall and described another analyst rating cut, underscoring that multiple firms responded to the clinical update.
The weekly report said Citizens saw few near-term catalysts in Foghorn’s remaining assets and considered the company’s market value high relative to its cash. These assessments belong to the analyst; the company’s announcement established the decision on FHD-909, but did not by itself settle the prospects of its other programs.
Gurit slides despite UBS lifting its target
Friday’s highlighted call concerned Gurit Holding. UBS downgraded the Swiss composites manufacturer to Neutral from Buy, even as it raised its 12-month price target to CHF57 from CHF49. Investing.com reported the shares fell 11.5% to CHF50.80, while contemporaneous coverage put the decline at roughly 11%.
UBS’s concerns centered on valuation after a steep rally: the roundup said the bank considered the shares fully valued after they had quadrupled since January 2026. It also pointed to a possible slowdown in growth into 2027, with wind-energy materials accounting for about 55% of sales. The higher target did not prevent the shares from falling, illustrating that a rating change and a target-price revision can send different signals.
Across the week’s five selected calls, the reported reasons ranged from credit exposure at FS KKR Capital to clinical evidence at Foghorn and valuation concerns at Gurit and Commerzbank. The roundup’s selection method highlights noticeable reactions, but the reported moves were snapshots and not a standardized comparison of full-session returns. No subsequent company announcements or scheduled follow-up events were identified in the weekly account as necessary to resolve the analysts’ differing assessments.
